Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer

NCT04450836 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT04450836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04450836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Terminated
Start date
November 23, 2020
Completion date
December 31, 2024
Enrollment
234 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer